(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of -13.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Taysha Gene Therapies's revenue in 2024 is $14,156,000.On average, 3 Wall Street analysts forecast TSHA's revenue for 2024 to be $2,714,757,280, with the lowest TSHA revenue forecast at $2,550,929,271, and the highest TSHA revenue forecast at $3,003,513,497. On average, 3 Wall Street analysts forecast TSHA's revenue for 2025 to be $2,118,917,056, with the lowest TSHA revenue forecast at $1,496,146,200, and the highest TSHA revenue forecast at $2,616,385,667.
In 2026, TSHA is forecast to generate $1,788,829,800 in revenue, with the lowest revenue forecast at $935,091,375 and the highest revenue forecast at $2,642,568,226.